Event Details ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial August 3, 2022 Supporting Materials AAIC22_ACT-AD-Phase-2-Trial-Presentation.pdf 4.1 MB Plain Language Summary — ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial 8.7 MB < SIGN UP FOR EMAIL ALERTS CONTACT IR
ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial August 3, 2022 Supporting Materials AAIC22_ACT-AD-Phase-2-Trial-Presentation.pdf 4.1 MB Plain Language Summary — ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial 8.7 MB
Plain Language Summary — ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial 8.7 MB
